CTRI/2021/01/030455
Active, not recruiting
未知
Seroprevalence of SARS-CoV2 Specific IgG Antibodies Among Blood Donors
ivetha M0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- ivetha M
- Status
- Active, not recruiting
- Last Updated
- 4 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All healthy eligible blood donors who are willing to Participate in the study
Exclusion Criteria
- •Blood Donors who are not willing to participate in the study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Seroprevalence of anti-SARS-CoV-2 antibody in response to COVID-19 vaccine in patients with i nflammatory bowel diseaseKCT0006901Keimyung University Dongsan Hospital150
Completed
Not Applicable
Seroprevalence of SARS-CoV-2 antibodies among healthcare workers with differing risk of exposureCOVID-1910047438NL-OMON49447niversitair Medisch Centrum Groningen600
Recruiting
Not Applicable
Seroprevalence of SARS CoV-2 infections/Covid-19 in blood donors and patients of the University Hospitals in LeipzigU07.1COVID-19, virus identifiedDRKS00023364Institut für Medizinische Mikrobiologie und Virologie, Universitätsklinikum Leipzig2,000
Recruiting
Not Applicable
SARS-CoV-2-IgG-titer of antibodies in helathcare workers after recovery or vaccinatio07.1 COVID-19DRKS00026288Evangelische Kliniken Gelsenkirchen800
Completed
Not Applicable
Seroprevalence of SARS-CoV-2 antibodies in a quarantined community after a COVID-19 outbreak-the CoNAN study07.1 COVID-19DRKS00022416niversitätsklinikum Jena626